Predictmedix Announces AI-Powered Mobile App for Rapid Detection of Alcohol and Cannabis-Induced Impairment
Predictmedix has begun production of its mobile app to detect health damage from cannabis and alcohol
Predictmedix screening to identify damage takes less than 30 seconds
The mobile app, powered by artificial intelligence algorithms currently used in Safe Entry, is accompanied by a “mini” multispectral imaging camera, resulting in a portable, non-invasive damage detection solution.
Commercialization specifically targets law enforcement, transportation, and other high-risk mobile industries
TORONTO, ON / ACCESSWIRE / March 15, 2023 / Predictmedix Inc. (“Predictmedix” or the “Company”) (CSE:PMED) (OTCQB:PMEDF) (FRA:3QP), an emerging provider of proprietary artificial intelligence (AI)-based rapid healthcare screening solutions, today announced that AI- based mobile application along with a portable multispectral imaging camera that non-invasively detects alcohol and cannabis-induced impairment. The non-invasive solution is being commercialized with the intention of serving global law enforcement, transportation and other high-risk mobile industries where impairment remains a significant liability. The Company’s recent studies have shown that its screening device can accurately identify injured persons with a success rate of over 90%. In addition, the screening process takes less than 30 seconds, making it a fast and reliable way to identify damage. Although cannabis breathalyzers are still in the early stages of development, according to the National Automobile Association, breathalyzers have a margin of error of up to 50%.1.
Alcohol and cannabis-related impairment is an ongoing problem for law enforcement agencies and high-risk industries worldwide – and current testing protocols are long, expensive and burdensome. Drug testing companies have failed to create a reliable, fast, cost-effective and non-invasive product in one product. Designed for law enforcement and other high-risk mobile industries, Predictmedix’s portable solution solves problems that companies and organizations have faced for years.
A multi-parameter approach is used to identify unique and specific features based on facial and speech analysis, which are analyzed by artificial intelligence algorithms, resulting in an unbiased result. The multispectral imaging camera captures invisible wavelength data from which AI algorithms extract features associated with impairment from alcohol and/or cannabis. Artificial intelligence is self-learning by nature, and Predictmedix’s algorithms improve as more data is acquired and processed, resulting in greater accuracy and speed over time.
Although the combination of multispectral imaging and speech analysis resulted in more than 90% accuracy in identifying impaired individuals, the speech analysis component of the solution alone achieved an impressive accuracy rate in identifying impairment. Predictmedix recognizes that this particular use case lies with the end user and is currently taking steps to preserve the rights and intellectual property of the technology for commercialization efforts and shareholder interests.
“We are pleased to announce to our shareholders that we have made very good progress with our portable solution for the detection of impairment in the health of individuals. Based on our research and discussions with high-level contacts, we believe that our product will be in high demand in many industry verticals. In 2021, the value of the drug screening market was more than 5.2 billion dollars and in 2030 they expect more than 22 billion dollars in revenue.2making this another profitable opportunity for Predictmedix,” commented Dr. Rahul Kushwah, Chief Operating Officer of Predictmedix. “We look forward to hearing from our shareholders on further technological and commercial developments.”
About Predictmedix Inc
Predictmedix (CSE:PMED) (OTCQB:PMEDF) (FRA:3QP) is an emerging provider of rapid healthcare screening and remote patient care solutions worldwide. Powered by proprietary artificial intelligence (AI), the company’s secure access stations use multispectral cameras to analyze patterns in physiological data and predict various health issues, including infectious diseases such as COVID-19, drug or alcohol impairment, fatigue or various mental problems. diseases. Predictmedix’s proprietary remote patient care platform empowers healthcare professionals with AI-driven tools to improve patient health. For more information, visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn.
Public Relations contact
For more media information or to arrange an interview, please contact:
Hudes Communications International
(905) 660 9155
Dr. Rahul Kushwah
(647) 889 6916
Caution regarding forward-looking information:
This press release may contain forward-looking statements and information based on current expectations. These statements should not be construed as a guarantee of the Company’s future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that could cause actual results, performance or results to differ materially from those expressed in such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that these assumptions will prove to be correct. We are not responsible for updating or revising them to reflect new events or circumstances. The Company’s securities have not been registered under the United States Securities Act of 1933 (the US Securities Act) or applicable state securities laws and may not be offered or sold to, for the account of, or for the benefit of, any person. in the United States or “US persons” as such term is defined in regulations under the United States Securities Act, in the absence of registration or an applicable exemption from such registration requirements. This press release does not constitute an offer to sell or the solicitation of an offer to buy, and no sale of securities may be made in the United States or any jurisdiction where such offer, solicitation or sale would be unlawful. In addition, there are known and unknown risk factors that could cause the Company’s actual results, performance or results to differ materially from any future results, performance or performance expressed or implied by the forward-looking information contained herein, such as , but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular uncertainties related to COVID-19; risks related to factors beyond the Company’s control, including risks related to COVID-19; risks related to the Company’s shares, including price fluctuations due to events that may or may not be within the control of that party; reliance on management; and emergency of additional competitors in the industry.
All forward-looking information provided herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update such forward-looking information or to publicly announce the results of any changes to the forward-looking information contained herein. to reflect future results, events or developments, except as required by law.
Disclaimer: “The Company does not currently make any express or implied claims that its product can diagnose, eliminate, cure or limit COVID-19 (or the SARS-2 coronavirus).
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ASSUME RESPONSIBILITY FOR THE SUITABILITY OR ACCURACY OF THIS ANNOUNCEMENT.
SOURCE: PredictMedix Inc.
Check out the source version on accesswire.com: